June 29, 2022 at 10:59 am #131737
Ah, found the information that I had previously posted…
https://www.bumc.bu.edu/endo/clinics/transgender-medicine/guidelines/
This link from the Boston University School of Medicine includes the medication and monitoring regimes for F>M and M>F.
Monitoring for transgender women (MTF) on hormone therapy:
- Monitor for feminizing and adverse effects every 3 months for first year and then every 6– 12 months.
- Monitor serum testosterone and estradiol at follow-up visits with a practical target in the female range (testosterone 30 – 100 ng/dl; E2 <200 pg/ml).
- Monitor prolactin and triglycerides before start- ing hormones and at follow-up visits.
- Monitor potassium levels if the patient is taking spironolactone.
- BMD screening before starting hormones for patients at risk for osteoporosis. Otherwise, start screening at age 60 or earlier if sex hormone levels are consistently low.
- MTF patients should be screened for breast and prostate cancer appropriately.